Neonatal Ağır Hiperparatiroidizm: Bir Olgu Sunumu
GİRİŞ: Neonatal ağır hiperparatiroidizm (NSHPT), kalsiyum algılayan reseptör (CaSR) geninde
meydana gelen homozigot- inaktive edici mutasyonların neden olduğu, nadir görülen bir hastalıktır. Bu
bebeklerde doğumdan hemen sonra ağır hiperkalsemi, hiperparatiroidizm, yaşamı tehdit edici kemik
hastalığı, respiratuar distress sendromu ve gelişme geriliği gözlenir. Eğer neonatal dönemde acil olarak
total paratiroidektomi yapılmaz ise ölümcül olabilir veya yaşayanlarda ağır nöro-gelişimsel sekel
bırakır.
OLGU SUNUMU: Üç günlükken NSHPT tanısı konulan, klasik hiperkalsemi tedavisi ve pamidronat
infüzyonlarına cevap vermediği için yaşamın üçüncü ayında subtotal paratiroidektomi yapılan
NSHPT’li bir olgu sunulmuştur. Hastamızın serum kalsiyum ve parathormon düzeyleri cerrahiden
hemen sonra normal düzeylere indi. Ancak bir yaşında iken yapılan kontrolünde orta derecede
hiperkalsemi ile beraber normal düzeyinin üst sınırında PTH düzeyleri saptandı.
Bu yazıda NSHPT’li bir süt çocuğunun takip ve tedavisinde edindiğimiz tecrübe anlatılmıştır.ABSTRACT
Introduction: Neonatal severe hiperparathroidism (NSHPT) due to homozygous inactivating mutations
in the CaSR gene is a very rare disease. NSHPT manifests severe hypercalcemia, hyperparathyroidism
and life-threatening bone disease, respiratory distress syndrome and failure to thrive shortly after birth.
If total parathyroidectomy is not performed urgently during the neonatal period, it can be fatal or result
in devastating neurodevelopmental complications in the survivors.
Case Report: An infant diagnosed with NSHPT at 3 days of age is presented here. Since, the
hypercalcemia did not respond to the classical treatment of hypercalcemia and pamidronate infusions,
subtotal parathroidectomy was performed at three month of age. The serum calcium and parathyroid
hormone (PTH) levels decreased to the normal levels immediately after the surgery. Butt, moderate
hypercalcemia with upper limits of normal PTH levels were determined. at one year of age.
Herein, we report our experience in treatment and follow-up of an infant with NSHPT.
___
- 1. Egbuna OI, Brown EM. Hypercalcaemic and hypocalcaemic conditions due to calcium-sensing
receptor mutations. Best Pract Res Clin Rheumatol 2008;22:129-48.
- 2. Arnold A, Lautre K. Genetics of hyperparathroidism including parathroid cancer. In: Genetic
diagnosis of endocrine disorders. Weiss RE, Refetoff S (eds). first edition. USA: Elsevier Comp;
2010. p. 141-8.
- 3. Varghese J, Rich T, Jimenez C. Benign familial hypocalciuric hypercalcemia. Endocr Pract
2011;17:13-7.
- 4. Pearce S, Steinmann B. Casting new light on the clinical spectrum of neonatal severe
hyperparathyroidism. Clin Endocrinol 1999;50:691-3.
- 5. Fox L, Sadowsky J, Kevin P, Kidd A, Murdoch J, David E.C, et al. Neonatal
hyperparathyroidism and pamidronate therapy in an extremely premature infant. Pediatrics
2007;120:1350-4.
- 6. Obermannova B, Banghova K, Sumnik Z, Dvorakova HM, Betka J, Fencl F, et al. Unusually
severe phenotype of neonatal primary hyperparathyroidism due to a heterozygous inactivating
mutation in the CASR gene. Eur J Pediatr 2009;168:569-73.
- 7. . Bai M, Pearce SH, Kifor O, Trivedi S, Stauffer UG, Thakker RV, et al. In vivo and in vitro
characterization of neonatal hyperparathyroidism resulting from a de novo, heterozygous
mutation in the Ca-sensing receptor gene: normal maternal calcium homeostasis as a cause of
secondary hyperparathyroidism in familial benign hypocalciuric hypercalcemia. J Clin Invest
1997;99:88-96.
- 8. Waller S, Kurzawinski T, Spitz L, Thakker R, Cranston T, Pearce S, et al. Neonatal severe
hyperparathyroidism: genotype/phenotype correlation and the use of pamidronate as rescue
therapy. Eur J Pediatr 2004;163:589-94.
- 9. Al-Khalaf FA, Ismail A, Soliman AT, Cole DE, Ben-Omran T. Neonatal severe
hyperparathyroidism: further clinical and molecular delineation. Eur J Pediatr 2011;170:625-
31.
- 10. Reh CM, Hendy GN, Cole DE, Jeandron DD. Neonatal hyperparathroidism with a heterozygous
calcium-sensing receptor (CaSR) R185Q mutation: clinical benefit from cinacalcet. J Clin
Endocrinol Metab 2011;96:E707-12.
- 11. Cohen A, Silverberg SJ. Calcimimetics: therapeutic potential in hyperparathyroidism. Curr
Opin Pharmacol 2002;2:734-9.
- 12. Brown EM. Clinical utility of calcimimetics targeting the extracellular calcium-sensing
receptor (CaSR). Biochem Pharmacol 2010;80:297-307.
- 13. Timmers HJ, Karperien M, Hamdy NA, de Boer H, Hermus AR. Normalization of serum
calcium by cinacalcet in a patient with hypercalcaemia due to de novo inactivating mutation of
the calcium-sensing receptor. J Intern Med 2006;260:177-82.
- 14. Alon US. VandeVoorde RG. Beneficial effect of cinacalcet in a child with familial
hypocalciuric hypercalcemia. Pediatr Nephrol 2010;25:1747-50.
- 15. Al-Shanafey S, Al-Hosaini R, Al-Ashwal A, Al-Rabeeah A. Surgical management of severe
neonatal hyperparathyroidism: one center's experience. J Pediatr Surg. 2010;45:714-7.
- 16. Pearce SH, Trump D, Wooding C, Besser GM, Chew SL, Grant DB, et al. Calcium-sensing
receptor mutations in familial benign hypercalcemia and neonatal hyperparathyroidism. J Clin
Invest 1995;96:2683-92.
- 17. Lam CW, Lee KF, Chan AO, Poon PM, Law TY, Tong SF. Novel missense mutation in the
CASR gene in a Chinese family with familial hypocalciuric hypercalcemia. Clin Chim Acta
2005;360:167-72.